793 related articles for article (PubMed ID: 22770231)
1. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
[TBL] [Abstract][Full Text] [Related]
2. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
[TBL] [Abstract][Full Text] [Related]
3. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Violari A; Lindsey JC; Hughes MD; Mujuru HA; Barlow-Mosha L; Kamthunzi P; Chi BH; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P
N Engl J Med; 2012 Jun; 366(25):2380-9. PubMed ID: 22716976
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Meyers TM; Yotebieng M; Kuhn L; Moultrie H
Pediatr Infect Dis J; 2011 Nov; 30(11):974-9. PubMed ID: 21734620
[TBL] [Abstract][Full Text] [Related]
6. The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
Barlow-Mosha LN; Bagenda DS; Mudiope PK; Mubiru MC; Butler LM; Fowler MG; Musoke PM
Afr Health Sci; 2012 Sep; 12(3):249-58. PubMed ID: 23382737
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
[TBL] [Abstract][Full Text] [Related]
8. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
[TBL] [Abstract][Full Text] [Related]
12. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
Thuret I; Michel G; Chambost H; Tamalet C; Giraud P; Brunet C; Perrimond H
AIDS; 1999 Jan; 13(1):81-7. PubMed ID: 10207548
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
[TBL] [Abstract][Full Text] [Related]
14. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
15. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
17. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
[TBL] [Abstract][Full Text] [Related]
18. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
19. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]